Their own payment-practices filing · gov.uk
Glaxosmithkline UK Limited pays suppliers in 41 days on average — inside its 60-day stated terms
Their H1 2026 filing puts the average 19 days inside their stated 60-day term.
- Their stated terms
- 60 days
- Paid outside agreed terms
- 2% of invoices
- Paid after 61+ days
- 5%
- Reporting period
- 1 Jan 2026 – 30 Jun 2026
- Source
- their gov.uk filing, filed 22 Jul 2026
Self-reported figures from their statutory filing. How this is compiled.
Terms vs reality · their H1 2026 filing
Paid 19 days inside the 60-day term they state
Where their invoices landed · share of all invoices
The pattern · last 6 of 17 reports
48 → 41 days — getting faster
The read · computed from their figures
Glaxosmithkline UK Limited's H1 2026 filing puts their average at 41 days against stated terms of 60 days; 2% of invoices were paid outside agreed terms and 5% took 61 days or longer. Filed 22 Jul 2026.
The direction is faster: from 48 days in H2 2023 to 41 now — 7 days faster across their last 6 reports.
On the latest reported averages: Slower than 60% of the 815 large companies reporting in wholesale & retail trade.
That is 17 statutory periods on record (earliest H1 2018) — a historical record, not a promise for a new invoice.
What they tell their suppliers
In their own words · from the filing
Standard payment terms
Qualifying contracts for this entity contain a number of different payment periods: • Immediate • 30 days • 60 days • 45 days • 30 days and 5th of the following month • 60 days and 5th of the following month Payments are made from date of receipt of invoice.
Dispute resolution
We offer our suppliers the following support and service: • Enquiries and complaints can be logged through our Helpdesk support system (mail or telephone). Issues are often related to incorrect invoice submission, payment terms are not as per contract, PO details are wrong / nonexistent etc. Key performance metrics are monitored for quality of Helpdesk support. • Our Supplier web pages also include details and a link to our Speak Up channels that enable concerns to be raised, including channels managed independently of GSK and the option to do so anonymously, although naturally it helps in resolving matters if we know as much as possible about the issue and complainant. • We have invested in Customer Relationship Management (CRM) to ensure effective and independent supplier fol
Other information
1) Statistics Reported: Intercompany invoices and performance have been excluded from reported statistics as these are generally wholly owned group companies and would distort performance if included. 2) Payment terms for SMEs and 'Paid on Time' monitoring: Preferential payment terms of 30 days are put in place for vendors that are confirmed as SMEs (Small and Medium Enterprises). We closely monitor our KPIs on a weekly basis to ensure that vendors (including SMEs) are paid on time. Corrective actions are taken to remedy any late payment issues where these are within the entity’s control. 3) Prompt Payment Code GSK relies on our suppliers to enable us to do business, and we want our suppliers to know they can rely on us, too. To achieve this, we believe it is important for GS
Every statutory report on record
Most recent first.
| Period | Avg days | Outside terms | 61+ days | Filed |
|---|---|---|---|---|
| H1 2026 | 41 | 2% | 5% | 22 Jul 2026 |
| H2 2025 | 36 | 1% | 4% | 26 Jan 2026 |
| H1 2025 | 38 | 2% | 6% | 29 Jul 2025 |
| H2 2024 | 45 | 2% | 3% | 31 Jan 2025 |
| H1 2024 | 51 | 2% | 11% | 30 Jul 2024 |
| H2 2023 | 48 | 4% | 7% | 30 Jan 2024 |
| H1 2023 | 47 | 5% | 11% | 27 Jul 2023 |
| H2 2022 | 53 | 7% | 26% | 27 Jan 2023 |
| H1 2022 | 53 | 4% | 6% | 28 Jul 2022 |
| H2 2021 | 45 | 4% | 8% | 28 Jan 2022 |
| H1 2021 | 50 | 4% | 11% | 29 Jul 2021 |
| H2 2020 | 53 | 3% | 26% | 28 Jan 2021 |
| H1 2020 | 73 | 7% | 78% | 29 Jul 2020 |
| H2 2019 | 72 | 3% | 84% | 29 Jan 2020 |
| H1 2019 | 76 | 6% | 88% | 30 Jul 2019 |
| H2 2018 | 75 | 8% | 85% | 31 Jan 2019 |
| H1 2018 | 78 | 7% | 88% | 30 Jul 2018 |
On the public register · Companies House
Company record
- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 24 Oct 2001
- Registered office
- 79 NEW OXFORD STREET, LONDON, WC1A 1DG
Quick answers · Glaxosmithkline UK Limited
Are they getting slower or faster?
What's their typical pay point?
Can I see what this means for my invoices?
Stay ahead
Watch Glaxosmithkline UK Limited (free)
Their next payment report is due ≈ 26 Jan 2027. We watch their public record and email you when something changes — a new payment report, late filings, insolvency markers, new charges.
You’ll get a confirmation email first. Unsubscribe any time. How we handle your address.
More large companies in wholesale & retail trade
Glaxosmithkline Export Limited · Glencore Agriculture UK Ltd. · Glaxosmithkline Consumer Healthcare (UK) Trading Limited · Global Life Sciences Solutions Operations UK Ltd · Glasswells Limited · Gloucestershire Gateway Limited
How UK payment reporting works
What is a Payment Practices Report?
What does "paid outside agreed terms" mean?
How often is this data updated?
Is this official government data?
How this is compiled. Built from official records only: Companies House and the gov.uk payment-practices service. The payment figures are self-reported — companies over the size threshold must file them by law and the board signs them off. No credit-agency data. The numbers are theirs; the plain-English read is ours. This is information compiled from public records under the Open Government Licence v3.0 — not a credit rating and not advice.
The 31-day comparison figure is the median across 6,104 companies with a current statutory report — every sector pooled, not an average of sector medians (how the figure is built).
Report PL-04310159 · latest period to 30 Jun 2026
Built by YORXEN LTD · registered in England & Wales · CRN 17303256 · privacy · terms.